Skip to main content
Top

27-07-2017 | Head and neck cancers | Article

Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas

Journal: Journal of Cancer Research and Clinical Oncology

Authors: Huaising C. Ko, Paul M. Harari, Ryan M. Sacotte, Shuai Chen, Aaron M. Wieland, Menggang Yu, Andrew M. Baschnagel, Justine Y. Bruce, Randall J. Kimple, Matthew E. Witek

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

We examined overall survival in a large cohort of patients with human papillomavirus (HPV)-positive and HPV-negative non-oropharyngeal squamous cell carcinoma of the head and neck (non-OPSCC).

Methods

Patients diagnosed with non-OPSCC and known HPV status were identified in the National Cancer Database (NCDB). Multivariate logistic regression was applied to examine factors associated with HPV status. Multivariate analysis was utilized to determine factors correlated with overall survival. Propensity score-weighted Kaplan–Meier estimation was used to adjust for confounders in survival analyses. Multiple imputation method was used for sensitivity analysis.

Results

We identified 19,993 non-OPSCC patients with 5070 being positive for HPV in the NCDB. Median follow-up was 23.5 months. HPV-positive patients were more commonly male, white, with a lower comorbidity index score, presenting with T-stage <2, and N-stage ≥1. Unadjusted 3-year overall survival was 62% and 80% for HPV-negative and HPV-positive patients, respectively (p < 0.0001). On multivariate analysis, mortality was reduced for HPV-positive patients with early stage (HR = 0.68) and locally advanced disease (HR = 0.46). Adjusted 3-year overall survival was 65% for HPV-negative and 76% for HPV-positive patients (p < 0.0001). The survival advantage of HPV was maintained in all subsites and robust on sensitivity analysis.

Conclusions

Patients with HPV-positive non-OPSCC exhibit similar characteristics as HPV-positive OPSCC. Overall survival was significantly higher for patients with HPV-positive versus HPV-negative non-OPSCC. These data reveal that HPV-positive non-OPSCC represent a favorable cohort that warrants recognition in the design of future clinical trial investigation.
Literature
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35CrossRefPubMedPubMedCentral
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29(32):4294–4301CrossRefPubMedPubMedCentral
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT (2014) p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32(35):3930–3938CrossRefPubMedPubMedCentral
Clayman GL, Stewart MG, Weber RS, el-Naggar AK, Grimm EA (1994) Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg 120(7):743–748CrossRefPubMed
Dahlstrom KR, Calzada G, Hanby JD, Garden AS, Glisson BS, Li G, Roberts DB, Weber RS, Sturgis EM (2013) An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer 119(1):81–89CrossRefPubMed
D’Souza G, Anantharaman D, Gheit T, Abedi-Ardekani B, Beachler DC, Conway DI, Olshan AF, Wunsch-Filho V, Toporcov TN, Ahrens W, Wisniewski K, Merletti F, Boccia S, Tajara EH, Zevallos JP, Levi JE, Weissler MC, Wright S, Scelo G, Mazul AL, Tommasino M, Brennan P, Cadoni G (2016) Effect of HPV on head and neck cancer patient survival, by region and tumor site: a comparison of 1362 cases across three continents. Oral Oncol 62:20–27CrossRefPubMed
Elango KJ, Suresh A, Erode EM, Subhadradevi L, Ravindran HK, Iyer SK, Iyer SK, Kuriakose MA (2011) Role of human papilloma virus in oral tongue squamous cell carcinoma. Asian Pac J Cancer Prev 12(4):889–896PubMed
Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, Soulieres D, Trotti A, Avizonis V, Ridge JA, Harris J, Le QT, Gillison M (2014) Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32(30):3365–3373CrossRefPubMedPubMedCentral
Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, Yin LX, Ryan WR, Ha PK, Wentz A, Koch W, Richmon JD, Eisele DW, D’Souza G (2017) The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer 123(9):1566–1575CrossRefPubMed
Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407–420CrossRefPubMed
Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK (2012) Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30(17):2102–2111CrossRefPubMedPubMedCentral
Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ (2011) Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck 33(11):1622–1627CrossRefPubMed
Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M (2012) Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 6(Suppl 1):S104–S120CrossRefPubMed
Kumar B, Cipolla MJ, Old MO, Brown NV, Kang SY, Dziegielewski PT, Durmus K, Ozer E, Agrawal A, Carrau RL, Schuller DE, Leon ME, Pan Q, Kumar P, Wood V, Burgers J, Wakely PE Jr, Teknos TN (2016) Surgical management of oropharyngeal squamous cell carcinoma: survival and functional outcomes. Head Neck 38(Suppl 1):E1794–E1802CrossRefPubMed
Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhoi BP, Overgaard M, Specht L, Andersen E, Johansen J, Andersen LJ, Grau C, Overgaard J, Danish H, Neck Cancer G (2011) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 100(1):49–55CrossRefPubMed
Lassen P, Primdahl H, Johansen J, Kristensen CA, Andersen E, Andersen LJ, Evensen JF, Eriksen JG, Overgaard J, Danish H, Neck Cancer G (2014) Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother Oncol 113(3):310–316CrossRefPubMed
Li F, Zaslavsky AM, Landrum MB (2013) Propensity score weighting with multilevel data. Stat Med 32(19):3373–3387CrossRefPubMedPubMedCentral
Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantu G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24(36):5630–5636CrossRefPubMed
Maier H, Dietz A, Gewelke U, Heller WD, Weidauer H (1992) Tobacco and alcohol and the risk of head and neck cancer. Clin Investig 70(3–4):320–327PubMed
Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, Lacau St Guily J (2015) Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 136(7):1494–1503CrossRefPubMed
Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA (2010) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28(27):4142–4148CrossRefPubMedPubMedCentral
Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New YorkCrossRef
Shaughnessy JN, Farghaly H, Wilson L, Redman R, Potts K, Bumpous J, Silverman C, Dunlap NE (2014) HPV: a factor in organ preservation for locally advanced larynx and hypopharynx cancer? Am J Otolaryngol 35(1):19–24CrossRefPubMed
Sivars L, Bersani C, Grun N, Ramqvist T, Munck-Wikland E, Von Buchwald C, Dalianis T (2016) Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. Mol Clin Oncol 5(6):671–674CrossRefPubMedPubMedCentral
Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP (2004) Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108(5):766–772CrossRefPubMed
Sugiyama M, Bhawal UK, Dohmen T, Ono S, Miyauchi M, Ishikawa T (2003) Detection of human papillomavirus-16 and HPV-18 DNA in normal, dysplastic, and malignant oral epithelium. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 95(5):594–600CrossRef